DSM Group: Kagocel Is Antiviral Drug No.1

DSM Group: Kagocel Is Antiviral Drug No.1


Kagocel is the leader in the volume of sales in real terms in the group of antiviral drugs for 2017 in Russia. According to DSM Group, its share amounted to 30.2% of the total market of antiviral drugs sold through pharmacies.  

The results of an audit give Kagocel every right to be named antiviral drug No. 1 in 2017. Kagocel has been holding a leading position in the rankings for the fifth consecutive year. In addition, the past year was a special one since it was marked by another important achievement. Kagocel was chosen as No.1 drug among the whole OTC segment, having taken the first place in the National Pharmaceutical Rating in the nomination "OTC Drug" due to its effectiveness and safety and, accordingly, to the high level of trust among specialists and consumers.

Reference:

DSM Group is a marketing agency specializing in pharmaceutical market research.

Kagocel is an original antiviral drug developed by Russian scientists for the treatment and prevention of influenza and SARS in adults and children from three years of age. The drug is released without a doctor's prescription, it is characterized by a high safety profile and a convenient regimen

The National Pharmaceutical Rating is a federal project in terms of its scope and scale, set up to assess the results in the pharmaceutical market in Russia. The rating takes into account the statistics of drugs purchased by and sold in pharmacies, clinics, and other medical institutions in Russia. The finalists of the rating are selected based on the data of DSM Group.



16.03.2018 09:11:00



← Back to the list

OUR AWARDS